Literature DB >> 8387391

p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

F S Leach1, T Tokino, P Meltzer, M Burrell, J D Oliner, S Smith, D E Hill, D Sidransky, K W Kinzler, B Vogelstein.   

Abstract

The p53 and MDM2 genes were analyzed in 24 human soft tissue sarcomas (11 malignant fibrous histiocytomas and 13 liposarcomas). Alterations of p53, consisting of point mutations, deletions, or overexpression, were detected in one-third (8 of 24) of the sarcomas. MDM2 gene amplification was detected in another 8 tumors, but no tumor contained an alteration of both genes. Monoclonal antibodies reactive with the human MDM2 gene product were developed, and immunohistochemical analysis revealed nuclear localization and overexpression of MDM2 in those tumors with amplified MDM2 genes. These data support the hypothesis that p53 and MDM2 genetic alterations are alternative mechanisms for inactivating the same regulatory pathway for suppressing cell growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  143 in total

1.  Choosing anticancer drug targets in the postgenomic era.

Authors:  W G Kaelin
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

5.  Aberrant AKT activation drives well-differentiated liposarcoma.

Authors:  Alejandro Gutierrez; Eric L Snyder; Adrian Marino-Enriquez; Yi-Xiang Zhang; Stefano Sioletic; Elena Kozakewich; Ruta Grebliunaite; Wen-Bin Ou; Ewa Sicinska; Chandrajit P Raut; George D Demetri; Antonio R Perez-Atayde; Andrew J Wagner; Jonathan A Fletcher; Christopher D M Fletcher; A Thomas Look
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

6.  Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

7.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 8.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 9.  Posttranscriptional regulation of p53 and its targets by RNA-binding proteins.

Authors:  Jin Zhang; Xinbin Chen
Journal:  Curr Mol Med       Date:  2008-12       Impact factor: 2.222

10.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; D Gasparotto; M Boiocchi; L Laurino; C D Fletcher
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.